Outputs (3)

Opportunities and challenges to delivering a trial for depressive symptoms in primary care during the COVID-19 pandemic: insights from the Alpha-Stim-D randomised controlled trial (2025)
Journal Article
Patel, S., Patel, P., Boutry, C., Guo, B., Butler, D., Higton, F., McNaughton, R., Briley, P. M., Griffiths, C., Nixon, N., Prasad, V., Sayal, K., Smart, D., Zafar, A., Kai, J., & Morriss, R. (2025). Opportunities and challenges to delivering a trial for depressive symptoms in primary care during the COVID-19 pandemic: insights from the Alpha-Stim-D randomised controlled trial. Trials, 26(1), Article 62. https://doi.org/10.1186/s13063-025-08772-3

Background: Randomised controlled trials (RCTs) are widely regarded as the most powerful research design for evidence-based practice. However, recruiting to RCTs can be challenging resulting in heightened costs and delays in research completion and i... Read More about Opportunities and challenges to delivering a trial for depressive symptoms in primary care during the COVID-19 pandemic: insights from the Alpha-Stim-D randomised controlled trial.

Acceptability, tolerability and safety of the BRIGhTMIND trial: Connectivity-guided intermittent theta-burst stimulation versus F3- repetitive transcranial magnetic stimulation for treatment-resistant depression. (2024)
Journal Article
Webster, L., Boutry, C., Thomson, L., Abdelghani, M., Barber, S., Briley, P. M., Kurkar, M., Lankappa, S., McAllister-Williams, R. H., Suazo Di Paola, A., & Morriss, R. (2025). Acceptability, tolerability and safety of the BRIGhTMIND trial: Connectivity-guided intermittent theta-burst stimulation versus F3- repetitive transcranial magnetic stimulation for treatment-resistant depression. Comprehensive Psychiatry, 136, Article 152544. https://doi.org/10.1016/j.comppsych.2024.152544

Background

The BRIGhTMIND study was a double-blind RCT comparing repetitive transcranial magnetic stimulation at a standard simulation site (the “F3” location given by the International 10–20 system, F3-rTMS) versus connectivity-guided intermitten... Read More about Acceptability, tolerability and safety of the BRIGhTMIND trial: Connectivity-guided intermittent theta-burst stimulation versus F3- repetitive transcranial magnetic stimulation for treatment-resistant depression..

Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial (2023)
Journal Article
Morriss, R., Patel, S., Boutry, C., Patel, P., Guo, B., Briley, P. M., Butler, D., Craven, M., Duncan, A., Griffiths, C., Higton, F., McNaughton, R., Nixon, N., Prasad, V., Sayal, K., Smart, D., Zafar, A., & Kai, J. (2023). Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial. Lancet Psychiatry, 10(3), 172-183. https://doi.org/10.1016/S2215-0366%2823%2900007-X

Background: Randomised sham-controlled trials of cranial electrostimulation with the Alpha-Stim Anxiety Insomnia and Depression (AID) device have reported improved anxiety and depression symptoms; however, no adequately powered sham-controlled trials... Read More about Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial.